Pfizer Inc. (PFE)

39.37
0.05 0.13
NYSE
Prev Close 39.42
Open 39.50
Day Low/High 39.16 / 39.64
52 Wk Low/High 34.32 / 46.47
Volume 20.11M
Exchange NYSE
Shares Outstanding 5551.81B
Market Cap 216.41B
Div & Yield N.A. (N.A)
U.S. Earnings Season Hits Stride With FAANG Reports but 2019 Outlook Weakens

U.S. Earnings Season Hits Stride With FAANG Reports but 2019 Outlook Weakens

U.S. corporate earnings have come in largely ahead of analysts' forecasts in the first two weeks of the reporting season, according to data from Refinitiv, but the rate at which companies are beating estimates continues to slip below both near and longer-term averages, suggesting the fading impact of tax cuts, and concerns about slowing global growth, could dampen profits over the first half of the year.

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

The Earnings Super Bowl: Cramer's 'Mad Money' Recap (Friday 1/25/19)

Jim Cramer's plan for getting through the heart of earnings season next week.

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

How to Trade Merck and Pfizer Pre-Earnings - Each Face Deteriorating Charts

Merck and Pfizer have been laggards so far in 2019. Technical warnings occurred on Dec. 4 when both set multiyear highs and both received downgrades.

Johnson & Johnson Tops Q4 Earnings Estimate, Sees 2019 Sales Near $81 Billion

Johnson & Johnson Tops Q4 Earnings Estimate, Sees 2019 Sales Near $81 Billion

Johnson & Johnson posted stronger-than-expected fourth quarter earnings Tuesday and forecast a modest increase in full year sales for 2019 that would take its top line past $81 billion.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Big pharma is shaping up to be a consolidating category in 2019.

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Power of Positives: Cramer's 'Mad Money' Recap (Thursday 1/17/19)

Jim Cramer talks about how this market is taking its cues from the positives, and shrugging off the negatives.

Takeda Pharmaceutical CEO Talks Big Pharma Trends

Takeda Pharmaceutical CEO Talks Big Pharma Trends

One of pharma's biggest CEO's talks M&A action on the exchange.

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon

Do we have to run for the hills? Not necessarily.

US FDA Accepts Regulatory Submissions For Review Of Tafamidis To Treat Transthyretin Amyloid Cardiomyopathy

US FDA Accepts Regulatory Submissions For Review Of Tafamidis To Treat Transthyretin Amyloid Cardiomyopathy

Pfizer Inc. (NYSE: PFE) announced today that the US Food and Drug Administration (FDA) accepted for filing the company's New Drug Applications (NDAs) for tafamidis for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Pfizer and the Urge to Merge

Pfizer and the Urge to Merge

My stated reason for being in Pfizer all along has been price stability and income.

This Market May Just Be in an Uptrend: Market Recon

This Market May Just Be in an Uptrend: Market Recon

This is the kind of reversal that happens in a bull market.

What Is Nasdaq and How Is It Different From the Dow?

What Is Nasdaq and How Is It Different From the Dow?

Nasdaq is an American stock market and the home of stocks that make up major indexes like the Nasdaq Composite and Nasdaq 100.

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference

We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.

Is Bristol-Myers Paying Too Much for Celgene?

Is Bristol-Myers Paying Too Much for Celgene?

BMY agreed to acquire CELG for $74 billion in cash and stock.

Pfizer Initiates Phase 2b/3 Clinical Trial For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Moderate To Severe Alopecia Areata

Pfizer Initiates Phase 2b/3 Clinical Trial For PF-06651600, An Oral JAK3 Inhibitor, For The Treatment Of Patients With Moderate To Severe Alopecia Areata

Pfizer Inc. (NYSE: PFE) announced today the initiation of a Phase 2b/3 clinical trial for its oral JAK3 inhibitor, PF-06651600, for the treatment of patients with moderate to severe alopecia areata, a chronic autoimmune skin disease that causes hair loss...

Pfizer Could Be a Healthy Option in This Volatile Market

Pfizer Could Be a Healthy Option in This Volatile Market

The health care sector may a good place to weather this storm. Here is why and how to play it.

This 2019 Market Optimism Is Misplaced: Market Recon

This 2019 Market Optimism Is Misplaced: Market Recon

Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, and Mikael Dolsten, President, Worldwide Research and Development, at the 37 th Annual J.

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap

Using Technical Analysis to Profit: Cramer's 'Mad Money' Recap

Jim Cramer explains the art and science of technical analysis.

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

See How Pfizer Ranks Among Analysts' Top Dow 30 Picks

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #24 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #355 spot.

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference

Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chief Operating Officer, at the Goldman Sachs 11 th Annual Healthcare CEOs Unscripted: A View from the Top on Thursday, January 3, 2019 at...

AbbVie: The Perfect Stock for High Yield and Growth

ABBV offers an ideal mix of growth, value and income.

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On JAVELIN Ovarian 100 Trial Of Avelumab In Previously Untreated Advanced Ovarian Cancer

Merck KGaA, Darmstadt, Germany, And Pfizer Provide Update On JAVELIN Ovarian 100 Trial Of Avelumab In Previously Untreated Advanced Ovarian Cancer

DARMSTADT, Germany, and NEW YORK, December 21, 2018 /PRNewswire/ -- Not intended for UK-based media Merck KGaA, Darmstadt, Germany, and Pfizer Inc.

Independent Data Monitoring Committee Recommends Discontinuation Of The Phase 2b STRIVE Clinical Trial Of Staphylococcus Aureus Vaccine Following Planned Interim Analysis

Independent Data Monitoring Committee Recommends Discontinuation Of The Phase 2b STRIVE Clinical Trial Of Staphylococcus Aureus Vaccine Following Planned Interim Analysis

Pfizer Inc. (NYSE:PFE) announced today that the Phase 2b trial STRIVE ( STaphylococcus aureus SuRgical Inpatient Vaccine Efficacy) evaluating the company's investigational Staphylococcus aureus ( S.

Https://www.astellas.com/us

Https://www.astellas.com/us

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.

Stocks Hit New Lows After Early Rally as Fed Hikes Key Rate

Stocks Hit New Lows After Early Rally as Fed Hikes Key Rate

Stocks plunged Wednesday afternoon following the Federal Reserve's decision to raise rates by a quarter point.

Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

Fed, Micron, Glaxo and Pfizer, FedEx and Facebook - 5 Things You Must Know

U.S. stock futures rise Wednesday as investors prep for an announcement from the Federal Reserve on interest rates; Micron tumbles after a weak second-quarter sales forecast; Glaxo and Pfizer combine their consumer health businesses; FedEx slumps after lowering its outlook.

GlaxoSmithKline, Pfizer Form Consumer Healthcare Group With $13 Billion in Sales

GlaxoSmithKline, Pfizer Form Consumer Healthcare Group With $13 Billion in Sales

GlaxoSmithKline shares surged to the top of the European market Wednesday after the drugmaker said it would combine its consumer health division with U.S. rival Pfizer's to create a new division with $13 billion in annual sales.

Pfizer And GlaxoSmithKline Announce Joint Venture To Create A Premier Global Consumer Healthcare Company

Pfizer And GlaxoSmithKline Announce Joint Venture To Create A Premier Global Consumer Healthcare Company

Pfizer Inc. (NYSE: PFE) and GlaxoSmithKline plc (NYSE:GSK) today announced they have entered into an agreement to create a premier global consumer healthcare company with robust iconic brands.

TheStreet Quant Rating: B (Buy)